ADMP
(NASDAQ)
0.3752
-0.0357  (-9.50%)
Volume (24h): 786.99K Day Range: 0.3651 - 0.4400
Market Cap: 23.20M 52W Range: 0.2730 - 2.30
Apr-01-20 01:00PM Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 PandemicGlobeNewswire
Mar-30-20 08:40PM Adamis Pharmaceuticals Announces 2019 Financial Results and Business UpdateGlobeNewswire
Feb-21-20 02:15PM Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct OfferingGlobeNewswire
Feb-19-20 02:00PM Adamis Pharmaceuticals Provides Update Regarding ZIMHIGlobeNewswire
Jan-04-20 02:31AM Edited Transcript of ADMP earnings conference call or presentation 12-Nov-19 10:00pm GMTThomson Reuters StreetEvents
Jan-03-20 08:57PM Edited Transcript of ADMP earnings conference call or presentation 12-Nov-19 10:00pm GMTThomson Reuters StreetEvents
Dec-23-19 08:59PM Adamis Pharmaceuticals Corporation (ADMP): Are Hedge Funds Right About This Stock?Insider Monkey
Dec-19-19 02:00PM Adamis Pharmaceuticals Provides an Update on ZIMHIGlobeNewswire
Dec-04-19 04:45AM Edited Transcript of ADMP earnings conference call or presentation 12-Nov-19 10:00pm GMTThomson Reuters StreetEvents
01:20AM Edited Transcript of ADMP earnings conference call or presentation 12-Nov-19 10:00pm GMTThomson Reuters StreetEvents
Nov-27-19 10:09PM Maxim’s Bullish Stance on Adamis (ADMP) Stock Comes to an EndTipRanks
Nov-25-19 08:16PM Adamis shares tumble after letter from FDAMarketWatch
01:44PM UPDATE 1-FDA declines to approve Adamis Pharma's Zimhi to treat opioid overdoseReuters
Nov-25-19 01:00PM Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHIGlobeNewswire
Nov-18-19 02:00PM Adamis Pharmaceuticals Announces Publication of Comparative Pharmacokinetics of Community Use Naloxone FormulationsGlobeNewswire
10:39AM Edited Transcript of ADMP earnings conference call or presentation 12-Nov-19 10:00pm GMTThomson Reuters StreetEvents
Nov-18-19 06:46AM Edited Transcript of ADMP earnings conference call or presentation 12-Nov-19 10:00pm GMTThomson Reuters StreetEvents
Nov-13-19 12:05AM Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Misses Revenue EstimatesZacks
Nov-12-19 09:28PM Adamis Pharmaceuticals Announces Third Quarter 2019 Financial Results and Business UpdateGlobeNewswire
Nov-07-19 01:54PM Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock OptionsZacks
Nov-06-19 09:05PM Adamis Pharmaceuticals Schedules Third Quarter 2019 Earnings Conference Call and Business UpdateGlobeNewswire
Nov-05-19 11:53AM The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 DisappointmentBenzinga
01:00AM Adamis Pharmaceuticals Provides Regulatory Update for Its Higher Dose Naloxone Pre-Filled SyringeGlobeNewswire
Nov-01-19 02:30PM Will Adamis Pharmaceuticals (ADMP) Report Negative Q3 Earnings? What You Should KnowZacks
Oct-18-19 10:26AM Could The Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ownership Structure Tell Us Something Useful?Simply Wall St.
Oct-08-19 01:00PM Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific MeetingGlobeNewswire
Oct-01-19 01:00PM Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New ZealandGlobeNewswire
Sep-26-19 01:00PM Adamis Pharmaceuticals Announces Presentation Pertaining to Its High Dose Naloxone Product Candidate at IHV Scientific MeetingGlobeNewswire
Sep-12-19 10:20AM Adamis Pharmaceuticals Corporation (NASDAQ:ADMP): What Does Its Beta Value Mean For Your Portfolio?Simply Wall St.
Sep-03-19 01:00PM Adamis Pharmaceuticals Provides Update for Naloxone Product CandidateGlobeNewswire
Aug-28-19 01:00PM Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPIGlobeNewswire
Aug-26-19 08:05PM Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of DirectorsGlobeNewswire
Aug-19-19 12:48PM Edited Transcript of ADMP earnings conference call or presentation 8-Aug-19 9:00pm GMTThomson Reuters StreetEvents
Aug-14-19 01:00PM Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding SubsidiaryGlobeNewswire
Aug-09-19 12:40AM Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue EstimatesZacks
Aug-08-19 08:30PM Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business UpdateGlobeNewswire
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)